GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Net Income

Scopus BioPharma (Scopus BioPharma) Net Income : $-8.70 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Scopus BioPharma's Net Income for the three months ended in Jun. 2023 was $-2.62 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-8.70 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Scopus BioPharma's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $-0.07.


Scopus BioPharma Net Income Historical Data

The historical data trend for Scopus BioPharma's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma Net Income Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial -0.69 -2.69 -10.86 -26.95 -11.61

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.32 -1.90 -1.73 -2.45 -2.62

Scopus BioPharma Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Scopus BioPharma's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-11.715+0+0+0.105
=-11.61

Scopus BioPharma's Net Income for the quarter that ended in Jun. 2023 is calculated as

Net Income(Q: Jun. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.929+0+0+0.312
=-2.62

Net Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scopus BioPharma  (OTCPK:SCPS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Scopus BioPharma's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Scopus BioPharma Net Income Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Scopus BioPharma (Scopus BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein director, officer: Chairman 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager officer: See Remarks 1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson director, officer: Vice Chairman 71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Iv David Weild director 22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel director SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein director C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper director 7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka director, officer: President 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005

Scopus BioPharma (Scopus BioPharma) Headlines

From GuruFocus

Scopus BioPharma to Present at the LD Micro Main Event

By Marketwired Marketwired 10-05-2021